Neuroblastoma Therapeutic Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Neuroblastoma Therapeutic Market is segmented By Treatment (Chemotherapy, Immunotherapy), By Drug Development Stage (Phase II, Phase I, Preclinical, Discovery), By Molecule Type (Recombinant fusion proteins, Small molecules, Monoclonal antibodies, Peptides, Polymers, Gene therapy), By Patient Population (Pediatric, Adolescents), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).The report offers the value (in USD billion) for the above-mentioned segments.

Neuroblastoma Therapeutic Market is segmented By Treatment (Chemotherapy, Immunotherapy), By Drug Development Stage (Phase II, Phase I, Preclinical, D....

Neuroblastoma Therapeutic Market Size

Market Size in USD

CAGR6.9%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	6.9%
Market Concentration	High
Major Players	United Therapeutics, AUM Biosciences, Cellectar Biosciences, Y-mAbs Therapeutics, Seagen Inc.

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

Neuroblastoma Therapeutic Market Analysis

The neuroblastoma therapeutic market is estimated to be valued at USD 2.78 Bn in 2024 and is expected to reach USD 4.44 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031. Rising drug approvals and emerging pipeline drugs to treat neuroblastoma are further supporting the market growth. Manufacturers are continuously focusing on developing novel therapeutics with improved efficacy and safety against neuroblastoma.

Neuroblastoma Therapeutic Market Report Snapshots

Buy Now